**Trabectedin Therapy**

**INDICATIONS FOR USE:**

<table>
<thead>
<tr>
<th>INDICATION</th>
<th>ICD10</th>
<th>Regimen Code</th>
<th>Reimbursement Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment of adult patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents</td>
<td>C49</td>
<td>00374a</td>
<td>Hospital</td>
</tr>
</tbody>
</table>

**TREATMENT:**

_The starting dose of the drugs detailed below may be adjusted downward by the prescribing clinician, using their independent medical judgement, to consider each patient's individual clinical circumstances._

Trabectedin is administered as an intravenous infusion over 24 hours once every 21 days until disease progression or unacceptable toxicity occurs.

<table>
<thead>
<tr>
<th>Day</th>
<th>Drug</th>
<th>Dose</th>
<th>Route</th>
<th>Diluent &amp; Rate</th>
<th>Cycle</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Trabectedin</td>
<td>1.5mg/m²</td>
<td>IV infusion</td>
<td>1000 ml 0.9% NaCl over 24 hours</td>
<td>Every 21 days</td>
</tr>
</tbody>
</table>

*Concentration of trabectedin in the infusion solution being ≤ 0.030 mg/ml. Intravenous administration through a central venous line is strongly recommended.

**ELIGIBILITY:**

- Indications as above
- ECOG performance status 0-1
- Adequate haematological, renal and hepatic function (see Table 1 above)

**EXCLUSIONS:**

- Hypersensitivity to trabectedin or any of the excipients
- Concurrent serious or uncontrolled infection

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient’s care or treatment. Use of these documents is the responsibility of the prescribing clinician. and is subject to HSE’s terms of use available at [http://www.hse.ie/eng/Disclaimer](http://www.hse.ie/eng/Disclaimer)

This information is valid only on the day of printing, for any updates please check [www.hse.ie/NCCPchemoregimens](http://www.hse.ie/NCCPchemoregimens)
NCCP Chemotherapy Regimen

- Breast-feeding
- Pregnancy

PRESCRIPTIVE AUTHORITY:
The treatment plan must be initiated by a Consultant Medical Oncologist

TESTS:

Baseline tests:
- FBC, liver and renal profiles, CPK
- MUGA or ECHO (to determine LVEF)

Regular tests:
- FBC, renal and liver profiles, CPK weekly during first two cycles of therapy and at least once between treatments in subsequent cycles.

Disease monitoring:
Disease monitoring should be in line with the patient’s treatment plan and any other test/s as directed by the supervising Consultant.

DOSE MODIFICATIONS:

- Any dose modification should be discussed with a Consultant.
- The same dose should be given for all cycles provided that no grade 3-4 toxicities are seen and that the patient meets the re-treatment criteria as shown in Table 1.
- If any of the events listed in table 2 occur at any time between cycles, the dose must be reduced one level, according to table 3 below, for subsequent cycles

| Table 2: Dose modification of trabectedin based on adverse events |
|-----------------|-----------------|
| Adverse event                                           | Dose Modification                                          |
| ANC < 0.5 x 10^9/L for > 5 days or associated with fever or infection | Reduce dose by one level according to table 3 below, for subsequent cycles. |
| Platelets < 25 x 10^9/L                                 | Once dose has been reduced dose escalation in the subsequent cycles is not recommended. |
| Increase of bilirubin > ULN and/or alkaline phosphatase > 2.5 x ULN | If any of these toxicities reappear in subsequent cycles in patient exhibiting clinical benefit, the dose may be further reduced (see Table 3). Colony stimulating factors can be administered for haematologic toxicity (Refer to local policy) |
| Increase of aminotransferases (AST or ALT) > 2.5 x ULN | |
| Any other grade 3 or 4 adverse reactions                | |

| Table 3: Dose modification table for trabectedin for soft tissue sarcoma |
|-----------------|-----------------|
| Starting dose                                           | 1.5mg/m² |
| First reduction                                         | 1.2 mg/m² |
| Second reduction                                         | 1 mg/m² |

NCCP Regimen: Trabectedin Monotherapy
Published: 11/11/2016
Review: 6/01/2026
Version number: 3

Tumour Group: Sarcoma
NCCP Regimen Code: 00374
ISM0 Contributor: Prof. Maccon Keane

Page 2 of 5

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient’s care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE’s terms of use available at http://www.hse.ie/eng/Disclaimer

This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens
Renal and Hepatic Impairment:

Table 4: Dose modification of trabectedin in renal and hepatic impairment

<table>
<thead>
<tr>
<th>Renal Impairment</th>
<th>Hepatic Impairment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Considering the pharmacokinetic characteristics of trabectedin, no dose adjustments are warranted in patients with mild or moderate renal impairment.</td>
<td>Special caution is advised and dose adjustments may be necessary in patients with hepatic impairment since systemic exposure is probably increased and the risk of hepatotoxicity might be increased. Patients with elevated bilirubin must not be treated with trabectedin</td>
</tr>
</tbody>
</table>

SUPPORTIVE CARE:

EMETOGENIC POTENTIAL: Moderate (Refer to local policy).

PREMEDICATIONS:
All patients must receive corticosteroids e.g. 20 mg of dexamethasone intravenously 30 minutes prior to trabectedin not only as anti-emetic prophylaxis, but also because it appears to provide hepatoprotective effects.

OTHER SUPPORTIVE CARE:
No specific recommendations

ADVERSE EFFECTS / REGIMEN SPECIFIC COMPLICATIONS
The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details.

- **Cardiac Dysfunction**: Patients should be monitored for cardiac-related adverse events or myocardial dysfunction. A thorough cardiac assessment including determination of left ventricular ejection fraction (LVEF) by echocardiogram or multigated acquisition scan (MUGA) should be conducted before initiation of trabectedin and at 2 to 3-month intervals thereafter until trabectedin is discontinued. Patients with LVEF less than the lower limit of normal (LVEF < LLN), prior cumulative anthracycline dose of >300mg/m², aged > 65 years, or a history of cardiovascular disease (especially in those with cardiac medication) may be at increased risk of cardiac dysfunction at treatment with trabectedin as monotherapy or in combination with doxorubicin. For patients with Grade 3 or 4 cardiac adverse events indicative of cardiomyopathy or for patients with a LVEF that decreases below the LLN (assessed as either an absolute decrease of LVEF of ≥15% or < LLN with an absolute decrease of ≥5%), trabectedin should be discontinued.

- **Rhabdomyolysis and severe CPK elevations (> 5 x ULN)**: Trabectedin must not be used in patients with CPK > 2.5 x ULN. Rhabdomyolysis has been uncommonly reported, usually in association with myelotoxicity, severe liver function test abnormalities and/or renal or multiorgan failure. Therefore, CPK should be closely monitored whenever a patient may be experiencing any of these toxicities or muscle weakness or muscle pain. If rhabdomyolysis occurs, supportive measures such as parenteral hydration, urine alkalisation and dialysis should be promptly established, as indicated. Treatment with trabectedin should be discontinued until the patient fully recovers. Caution should be taken if medicinal products associated with rhabdomyolysis (e.g. statins), are administered concomitantly with trabectedin, since the risk of rhabdomyolysis may be increased.
NCCP Chemotherapy Regimen

- **Injection site reactions**: The use of central venous access is strongly recommended. Patients may develop a potentially severe injection site reaction when trabectedin is administered through a peripheral venous line. Trabectedin extravasation may cause tissue necrosis requiring debridement.
- **Allergic Reactions**: During postmarketing experience, hypersensitivity reactions with very rare occurrence of fatal outcome, have been reported in association with trabectedin administration either alone or in combination with pegylated DOXOrubicin.

**DRUG INTERACTIONS:**

- Trabectedin is metabolized mainly by CYP3A4. Close monitoring of toxicities is required in patients receiving trabectedin in combination with potent CYP3A4 inhibitors and such combinations should be avoided if possible. If such combinations are needed, appropriate dose adjustments should be applied in the event of toxicities.
- Concomitant use of trabectedin with strong CYP3A4 inducers should be avoided if possible
- Alcohol consumption must be avoided during treatment with trabectedin due to the hepatotoxicity of the medicinal product
- Preclinical data have demonstrated that trabectedin is a substrate to P-gp. Concomitant administration of inhibitors of P-gp, e.g. cyclosporine and verapamil, may alter trabectedin distribution and/or elimination. The relevance of this interaction e.g. central nervous system (CNS) toxicity has not been established. Caution should be taken in such situations.
- Current drug interaction databases should be consulted for more information.

**ATC CODE:**
Trabectedin L01CX01

**REFERENCES:**

NCCP Regimen: Trabectedin Monotherapy

Published: 11/11/2016
Review: 6/01/2026
Version number: 3

NCCP Regimen Code: 00374
ISM0 Contributor: Prof. Maccon Keane

Comments and feedback welcome at oncologydrugs@cancercontrol.ie.